Pacific Biosciences Of California (PACB) EBT Margin (2010 - 2026)

Pacific Biosciences Of California's EBT Margin history runs 17 years deep, the most recent figure standing at 21.76% for Q1 2026.

• On a quarterly basis, EBT Margin rose 112586.0% year-over-year to 21.76% in Q1 2026; TTM through Mar 2026 was 79.84%, a 35186.0% increase from a year earlier, with the FY2025 full-year figure at 341.28%, down 14030.0% from the prior year.
• EBT Margin grew to 21.76% in Q1 2026 per PACB's latest filing, from 89.97% in the prior quarter.
• Across five years, EBT Margin topped out at 6.85% in Q4 2024 and bottomed at 1147.62% in Q1 2025.
• The 5-year median for EBT Margin is 151.94% (2024), against an average of 231.66%.
• Across the five-year window, EBT Margin tumbled 94619 bps in 2025 and surged 112586 bps in 2026, its largest moves.
• Year by year, EBT Margin stood at 308.5% in 2022, then surged by 54 bps to 141.78% in 2023, then surged by 105 bps to 6.85% in 2024, then tumbled by 1413 bps to 89.97% in 2025, then soared by 76 bps to 21.76% in 2026.
• Per Business Quant, the three latest PACB EBT Margin figures stand at 21.76% (Q1 2026), 89.97% (Q4 2025), and 97.86% (Q3 2025).